Leptin, Neuropeptide Y and Obesity

Gören DENİZ*, Şahan SAYGI**

* Ass.Prof.Dr., GATA, Department of Pharmacology,
** Ass.Prof.Dr., GATA, Department of Analytical Toxicology, Ankara, TURKEY

Summary

Obesity is a highly prevalent disorder that is associated with high mortality rate from related diseases such as cardiovascular and metabolic diseases. It is caused by an imbalance between energy intake and energy expenditure, which is influenced with both environmental and genetic factors.

The discovery of leptin has led to better understanding of the obesity. Leptin is a peripheral hormone produced by the adipocytes and is thought to play a key role in the regulation of energy balance. Leptin, the product of the obese gene, inhibits food intake, stimulates energy expenditure and reduces body weight possibly suppressing hypothalamic neuropeptide Y activity. Obesity in ob/ob mice is caused by a mutation in the ob gene resulting in a lack of functional leptin.

Leptin acts as a satiety factor by binding to receptors in the hypothalamus and the plasma levels of leptin are highly correlated with body fatty mass. Its expression increases after food intake and decreases during fasting and diabetes.

This review briefly summarizes the role of leptin and neuropeptide Y in the regulation of food intake and body weight.

Key Words: Leptin, Neuropeptide Y, Obesity


Özet

Kardiyovasküler ve metabolik hastalıklara yol açan ve yüksek ölüm oranını taşıyan şişmanlık oldukça yaygın bir rahatsızlık taşır. Enerji alımı ile enerji harcanması arasındaki dengesizliğe bağlı olarak gelişen şişmanlık hem çevresel hem de genetik faktörlerin etkisi altındadır.

Leptinin keşfi şişmanlığın daha iyi anlaşılmasına yol açmıştır. Leptin yağ hücrelerinde üretilen ve enerji dengesinin düzenlenmesinde anatara rolü oynadığı düşünülen bir periferik hormondur. Leptin bir obez gen ürünü olan olup muhtemelen ipotalaman bir hormon olan nöropeptid Y’yi baskılamak suretiyle besin alma, enerji harcanmasını stimüle eder ve vücut ağırlığını azaltır. Genetik olarak şişman olanlardaki leptin eksikliği sonucu meydana gelmektedir.

Leptin ipotalamustaki reseptörlerile bağlanarak bir doygunluk faktörü gibi hareket eder ve plazma seviyeleri vücut ağırlığını en yüksek korelasyon gösterir. Leptin ekspresyonunun öncesi ve ağırlığındaki rolüne nöropeptid Y’ye dair bir eksiklik sonucu meydana gelmektedir.

Bu derlemede leptin ve nöropeptid Y’nin besin alma ve vücut ağırlığını regulasyonundaki rolünü özetlemektedir.

Anahtar Kelimeler: Leptin, Nöropeptid Y, Şişmanlık


Obesity

Obesity is a common medical condition most often due to an imbalance between energy intake and expenditure (1). It is a major risk factor for morbidity and mortality from a variety of diseases including hyperlipidemia, hyperglycemia and hypertension. Studies indicated that obesity is the result of genetic, environmental and neuroendocrine factors. The regulation of weight and weight gain is a complex process that involves a number of behavioral, social and hormonal factors (2-4).

The process of the weight gain in obesity is more complex. The discovery of both leptin and Neuropeptide Y (NPY) has led to a better understanding of the pathophysiology of obesity (5-7). Several anatomic regions play a central role in regulating fat stores. The hypothalamus is indeed known to modulate food intake and energy partitioning. The mammalian hypothalamus strongly influences ingestive behavior through several different signaling molecules such as leptin, NPY and insulin (2). Damage to the ventromedial nucleus (VMN) or the paraventricular nucleus (PVN) in the hypothalamus produces massive obesity in mammals and birds. Injury to the central nucleus of amygdala will also produce obesity in contrast to the lateral hypothalamus (8).

The identification and sequencing of the mouse obese (ob) gene in 1994 opened important new avenues in obesity research (9,10). Leptin, the obese gene product, is produced by adipocytes and is secreted in plasma and acts particularly within the hypothalamus (11,12). It inhibits
food intake, stimulates energy expenditure and reduce body weight. NPY, the hypothalamic neurotransmitter is a potent stimulant of appetite and feeding which also reduce energy expenditure (13,14,15). The expression and release of hypothalamic NPY are inhibited by leptin (16). The interaction between leptin and NPY concentration has been considered an important factor in the regulation of body weight (17). Obese individuals have hyperleptinemia (18). It is believed that obesity is the result of resistance to leptin. The increase in plasma leptin levels observed with increasing adiposity, such as that obese humans may be resistant to the putative effects of leptin (19).

Obesity is a chronic medical condition that may require long term treatment, therefore the risks and benefits of all pharmacological agents must be carefully considered (1). The treatment of obesity requires modulation of both energy intake and energy expenditure, and pharmaceutical treatments are being developed to complement the traditional means of dietary restriction and exercise (20).

Obesity has now become a major target for drug development not only for affecting obesity but also for managing and preventing some conditions, such as diabetes and cardiovascular diseases (4).

**Leptin**

The discovery of a “fat melting hormone” named leptin (Greek root, lepto meaning thin) by Friedman JM raised the hopes in human obesity (21). In 1958, Hervey GR first demonstrated the presence of a hormone that regulated body weight through an interaction with the hypothalamus (22). The cloning and characterization of the ob gene had showed that it encodes a hormone, leptin, that is expressed in adipose tissue and lower levels in gastric epithelium and placenta (3,23). Identification of the obese (ob) gene and its protein product, leptin has increased understanding of the pathophysiology of obesity (6,20,24).

Leptin is synthesized in the adipocytes, circulates in the blood, binds the proteins, and acts on central neural networks especially in hypothalamus. It inhibits food intake, stimulates energy expenditure, and reduces body weight (14,16,25,26), and is postulated to act as a satiety factor by binding to receptors in the hypothalamus (27).

The first step to understand leptin action has been taken when Tartaglia, et al discovered the leptin receptor (Ob-R) (28). The effects of leptin suggest regulation at the level of the hypothalamus. Leptin receptors have been localized to the choroid plexus and hypothalamus. It was first isolated from mouse choroid plexus by expression cloning and identified as a member of the cytokine family of receptors. There are two major isoforms of the leptin receptors. First isoform, short leptin receptor (Ob-Ra) is believed to function as a transporter and it seems to be responsible for transporting leptin across the blood-brain barrier in the hypothalamus, this receptor is defective in obese diabetic db/db mice. Second isoform, long leptin receptor (Ob-Rb) is believed to function as the first leptin signaling step (3,14,29). Leptin receptors are expressed at different levels in different tissues of mice, mainly in the brain, heart, testes, and adipose tissues.

Leptin appears to play a major role in the control of body fat stores through coordinated regulation of feeding behavior, metabolism, energy balance, and autonomic nervous system in rodents, primates, and humans. It provides a communication link between fat tissue and brain, that is thought to be blood borne signal from the adipose tissue that informs the brain about the size of the body fat mass (19,30). There is a strong positive correlation between serum levels of leptin and adipose tissue mass. Leptin levels increase with increasing body fat. Therefore, serum leptin levels reflect the amount of adipose tissue in the body in humans and animals. Serum levels of leptin in normal weight subjects are in the 5 ng/ml range and reach 50 ng/ml in obese subjects. Weight gain leads to higher blood levels and weight loss to lower levels (5,31-33).

Leptin expression increases after food intake, and decreases during fasting and diabetes. Daily administration of recombinant leptin produces striking weight loss in the ob/ob mice. Furthermore, weight loss after leptin administration in animals is not only due to decreased appetite and food consumption, but also increase in thermogenesis and activity level (3,10,16,19).

The raised leptin levels in obese people have been interpreted as a consequence of relative insensitivity to endogenous leptin, possibly caused by deficient functioning of leptin receptors in the brain (29).

The aberrant secretion of leptin and deficient leptin receptor function have all been shown to cause obesity in animal models and humans. Leptin deficiency and/or receptor defects and resistance to leptin perception by specific brain centers, and reduced efficiency of leptin uptake into the hypothalamus have been proposed as possible mechanisms for unrestricted weight gain (2,31).

Leptin is an increasingly convincing candidate in the central regulation of energy homeostasis. However, many peripheral and central factors play a role on the effects of leptin such as insulin, NPY, glucocorticoids, melanocyte stimulating hormone, and galanin. Leptin is thought to influence energy homeostasis mainly by regulating the expression of hypothalamic neuropeptides, which then influence feeding behavior, autonomic and neuroendocrine function.

NPY is a critical component of the biological response to leptin levels. For example, levels of orexigenic peptide NPY are increased in the hypothalamus as a result
of leptin deficiency and starvation, and this over expression is decreased by leptin administration. This interaction may be important in regulating energy balance and body fat mass (16,34,35). Anabolic peptides are inhibited by leptin and catabolic peptides are stimulated by leptin. One of the leptin’s main effects may be to inhibit synthesis and release of hypothalamic NPY. It is hypothalamic neurotransmitter and potent stimulant of appetite and feeding which increases food intake and body weight (13,14,15,36). NPY is now recognized as an important endogenous appetite transducer. NPY producing neurons that participate in the daily management of feeding behavior are localized in the arcuate nucleus of the hypothalamus in the brain-stem (7). Levels of NPY are increased in the hypothalamus as a result of leptin deficiency in ob/ob mice (16,27,37,38). Chronic administration of NPY into the hypothalamus of normal animals mimics the phenotype of leptin deficiency including obesity and reduced thermogenesis. NPY deficiency does also partially ameliorate the obesity and all of the adverse endocrine effects of leptin deficiency in ob/ob mice, so NPY antagonists and leptin are of interest as potential anti obesity agents (4).

Leptin has been reported to normalize hyperglycemia and hyperinsulinemia in ob/ob mice (39,40). Experimental data suggest that insulin is an important regulator of leptin expression in adipose tissue. Moreover, leptin may have direct effect on insulin action (32,41). In ob/ob mice exogenous leptin lowers plasma insulin levels. Leptin circulates at concentrations proportionate to both body adiposity and plasma insulin levels. Recent studies showed such as a complex relationship between leptin and insulin or insulin resistance and obesity (6,17,23). The interaction between insulin insensitivity and leptin concentration may be important in the regulation of body weight. It has been hypothesized that insulin resistance itself protects against weight gain. Glucocorticoids have also an inhibitory effect on the action of leptin (42).

Anorexia nervosa patients have extremely low leptin levels. Re-feeding of these patients results in a rapid increase in plasma leptin concentration to roughly normal levels before normal weight is achieved. That is excessive leptin production plays a permissive role in the pathogenesis of this condition (3).

The mechanism by which centrally administrated leptin leads to lipolysis and the loss of adipose tissue mass is unknown. The metabolic response to leptin is markedly different from the response to reduced food intake. Whereas dieting leads to the loss of lean body mass and adipose tissue mass, leptin induces weight loss in specific for the adipose tissue mass.

The possible therapeutic benefit of leptin treatment in humans is now being studied in clinical trials. Studies show that four weeks of daily leptin injection (0.3 mg/kg) are safe and cause small but significant weight loss in lean and obese subjects. The ability to optimize the pharmacokinetics of recombinant leptin may greatly influence its usefulness. Administration of leptin by injection or with greater potency as a constant subcutaneous infusion results in a dose dependent decrease in body weight at incremental increases of plasma leptin levels within the physiological range. For example, leptin is more potent when administered as a subcutaneous infusion, whereas once-daily intraperitoneal injection is largely ineffective (33). The manipulation of leptin and NPY are under investigation for the treatment of obesity.

**Leptin Resistance**

In general, obese animals have higher leptin levels than controls, indicating that this form of animal obesity is associated with leptin resistance (3,15). The concentration of leptin in the peripheral circulation is about four fold higher in obese individuals compared with the lean. Thus, since the expected response to hyperleptinemia is decreased caloric intake and increased energy expenditure, most obese humans are probably insensitive to endogenous leptin production. In lean subjects with relatively low adipose tissue, the majority of circulating leptin is in the bound form. In obese individuals, the majority of leptin circulates in free form which is the bioactive protein, and thus obese subjects are resistant to free leptin (27).

The role of leptin in the pathogenesis of obesity may be the result of resistance of leptin. The basis for leptin resistance in obese hyperleptinemic human subjects is clearly unknown. The great majority of obese subjects don’t have a defect in the production of leptin. Leptin resistance can be due to a defect in transporter system (blood-brain barrier and blood-cerebrospinal barrier). Leptin transport may be normal but defect may lie in the leptin receptor. It is possible that both leptin transport and its receptor are normal and the defect lies in the signaling mechanism. Leptin resistance makes exogenous leptin less suitable as a treatment for obesity in humans.

The pathogenesis of most human obesity is unknown and likely to be result of disturbances in leptin secretion or leptin sensitivity. The relative importance of leptin, NPY and other peripheral signals of fat mass require further investigation.

**REFERENCES**


Chen MD, Song YM, Lin PY. Zinc may be a mediator of leptin production in humans. Life Science 2000; 66(22): 2143-9.


220